Clinical Study

A Randomized Phase III Trial Of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin For Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Posted Date: Mar 7, 2017

  • Investigator: Elizabeth Shaughnessy
  • Specialties: Breast Cancer, Hematology/Oncology, Oncology, Cancer, Surgical Oncology
  • Type of Study: Drug

The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin. The addition of carboplatin to the usual chemotherapy could prevent your cancer from returning, but it could also cause side effects. This study will allow the researchers to know whether giving carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy. If giving carboplatin with the usual chemotherapy drugs is better, there should be a higher chance that your breast cancer will not return. Carboplatin is FDA-approved for the treatment of cancer and is used for the treatment of breast cancer that has spread, but it has not yet been proven useful in earlier stages of breast cancer.

Criteria:

To Be Eligible To Participate, Patients Must Have A Type Of Breast Cancer That Is Her2-Negative And Is Not Sensitive To Hormone Treatment And Have Already Been Treated With Surgery.

Keywords:

Triple Negative, Breast, Node Negative/Positive, Nrg-Br003, Cancer

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu